Positions

Overview

  • 2/2001-11/2004 Postdoctoral Fellow, Department Molecular Pathology, The University of Texas, M. D. Anderson Cancer Center, Houston, TX (Dr. Kun-Sang Chang)

    12/2004-11/2009 Assistant Professor (Research), Department of Molecular Therapeutics (Department of Systems Biology), The University of Texas M. D. Anderson Cancer Center, Houston, TX.

    11/2009-present Assistant Professor (tenure track), Division of Hematology / Oncology & Comprehensive Cancer Center, The University of Alabama at Birmingham, Birmingham, AL
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2019 Targeting MC1R depalmitoylation to prevent melanomagenesis in redheads 2019
    2018 The protective role of DOT1L in UV-induced melanomagenesis 2018
    2018 Targeting the upstream transcriptional activator of PD-L1 as an alternative strategy in melanoma therapy 2018
    2018 Piperlongumine and p53-reactivator APR-246 selectively induce cell death in HNSCC by targeting GSTP1 2018
    2018 PARP-1 inhibitors sensitize HNSCC cells to APR-246 by inactivation of thioredoxin reductase 1 (TrxR1) and promotion of ROS accumulation 2018
    2017 Focal Adhesion Kinase Regulates Hepatic Stellate Cell Activation and Liver Fibrosis 2017
    2017 Palmitoylation-dependent activation of MC1R prevents melanomagenesis 2017
    2017 Over-expression of BAG-1 in head and neck squamous cell carcinomas (HNSCC) is associated with cisplatin-resistance 2017
    2017 LKB1 inhibits HPV-associated cancer progression by targeting cellular metabolism 2017
    2017 Celastrol induces apoptosis in hepatocellular carcinoma cells via targeting ER-stress/UPR 2017
    2016 O-linked GlcNAcylation elevated by HPV E6 mediates viral oncogenesis 2016
    2016 LKB1 is a DNA damage response protein that regulates cellular sensitivity to PARP inhibitors 2016
    2015 Myristoylation confers noncanonical AMPK functions in autophagy selectivity and mitochondrial surveillance 2015
    2015 LKB1 reduces ROS-mediated cell damage via activation of p38 2015
    2015 Recent advances in the study of HPV-associated carcinogenesis 2015
    2015 The E3 ligase APC/C<sup>Cdh1</sup> promotes ubiquitylation-mediated proteolysis of PAX3 to suppress melanocyte proliferation and melanoma growth 2015
    2015 The tissue dependent interactions between p53 and Bcl-2 in vivo 2015
    2013 TBX2 expression is regulated by PAX3 in the melanocyte lineage 2013

    Research Overview

  • The objectives in Dr. Xu's lab are to identify the molecular mechanisms underlying tumor suppressor function and to develop pharmacological agents that can modulate or mimic tumor suppressors for cancer prevention and treatment. Specifically, the lab currently has three research directions:
    (1) Tumor suppressor and genomic stability: (A) To investigate mechanisms of how tumor suppressors, such as LKB1 (also known as serine/threonine kinase 11, STK11), PML, and p53, regulate genomic stability; (B) To determine LKB1-related protein signatures and signaling networks under stressed conditions and identify novel LKB1-interacting proteins; (C) To define LKB1 expression (mutation) in tumors and its relationship to patient outcomes and therapeutic response.
    (2) Cell death---Autophagy and Necrosis: (A) To determine the role of autophagy in LKB1-mediated genomic stabilization; (B) To screen and characterize genes that regulate autophagy and necrosis in mammalian cells; (C) To determine the role of autophagy and necrosis in tumorigenesis and targeted therapy.
    (3) Molecular therapeutics: To develop pharmacologic agents targeting the LKB1-AMPK-mTOR pathway for cancer prevention and treatment.
  • Investigator On

    Education And Training

  • Doctor of Philosophy in Oncology and Cancer Biology, Soochow University 2000
  • Master of Science in Physiology, Pathology and Related Sciences, Nantong University 1990
  • Doctor of Medicine, Soochow University 1987
  • Full Name

  • Zhi-Xiang Xu
  • Fax

  • 205-934-1870